Reverse engineering the SARS-CoV2 virus variants for the rational design of anti-COVID-19 therapeutics

The current pandemic is caused by a nasty virus that infects mostly the lungs via a receptor critical for the virus to bind to lung cells. Knowing how the virus binds to its lung receptor will enable us to synthesize small experimental drugs that will be investigated further for interesting therapeutic properties. This proposal focuses on testing how the virus binds to cells, how exactly it happens, and how this can be used to develop drugs for the current and future pandemics.

Faculty Supervisor:

Pascal Bernatchez

Student:

Partner:

Providence Health Care

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Professional, scientific and technical services

University:

The University of British Columbia

Program:

Accelerate

Related projects

Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.

View all
Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects

Mitacs Partners

The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.

Government
Academic
Industry
Innovation
International

International

Load More

International

Load More

Join a thriving innovation ecosystem.

Subscribe to our newsletter now!

Subscribe

Mitacs — Return on Innovation

Mitacs is funded by the Government of Canada, the Government of Alberta, the Government of British Columbia, Research Manitoba, the Government of New Brunswick, the Government of Newfoundland and Labrador, the Government of Nova Scotia, the Government of Ontario, Innovation PEI, the Government of Quebec, the Government of Saskatchewan, and the Government of Yukon.